$120.85$150.99
Prepare to embark on a sensory journey with the Bosco Apple, a fruit that transcends the ordinary and promises an unparalleled taste experience. These apples are nothing short of nature’s masterpiece, celebrated for their distinctive blend of flavors and their captivating visual allure.
Availability: In Stock
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
₹701
INTRODUCTION EVERGRAF 0.25MG TABLET contains Everolimus which belongs to the group of medicines called Immunosuppressants. It is used for the prevention of organ rejection in transplant patients (organs like kidney or liver). It is also used together with other medicines, such as ciclosporin f...
EVERGRAF 0.25MG TABLET contains Everolimus which belongs to the group of medicines called Immunosuppressants. It is used for the prevention of organ rejection in transplant patients (organs like kidney or liver). It is also used together with other medicines, such as ciclosporin for the transplantation of kidney, tacrolimus for liver transplantation, and corticosteroids. Organ transplant rejection is when a new organ is transplanted into the body, our body recognizes it as a foreign element and tries to attack and reject it because it is not originally part of the body.
Before taking EVERGRAF 0.25MG TABLET, inform your doctor if you have or ever had recent major surgery, or if you still have an unhealed wound following surgery, skin cancer, high cholesterol, or triglycerides, Lapp lactase deficiency or glucose-galactose malabsorption, angioedema, heart problems, liver problems, and kidney problems.
EVERGRAF 0.25MG TABLET is not recommended for use in children and adolescents (below 18 years of age) and elders (65 years and above). EVERGRAF 0.25MG TABLET is generally not recommended for use among pregnant and breastfeeding women. The most common side effects of taking EVERGRAF 0.25MG TABLET are nausea, swelling of the lower legs, ankles, and feet, vomiting, diarrhea, stomach pain, infections, anemia, headache, anxiety. Contact your physician for advice if any of the symptoms worsen.
It is used:
EVERGRAF 0.25MG TABLET works by suppressing the activity of the body's immune system and preventing the rejection of the transplanted organ.
Take EVERGRAF 0.25MG TABLET as advised by your physician. Swallow the medicine with enough water. Do not crush or chew the EVERGRAF 0.25MG TABLET. The correct dose and duration will be decided by your physician for you depending on your age, body weight, and disease condition.
Stop taking EVERGRAF 0.25MG TABLET and contact your doctor immediately if you experience any of the following side effects:
Drink lots of fluids, such as water or fruit juice to keep yourself hydrated. Do not consume any medicine on your own without consulting your physician.
Take this medicine with, or just after meals. Stick to simple meals. Avoid eating oil-rich or spicy foods.
Try to rest and relax. Eat and drink gradually or try to have lesser and more frequent meals. Keep a heating pad on your stomach. Contact your physician for advice if the symptom does not improve.
EVERGRAF 0.25MG TABLET should not be given to pregnant women unless the potential benefit outweighs the potential risk to the fetus. Consult your doctor before taking it.
EVERGRAF 0.25MG TABLET is not recommended for use in breastfeeding women as it may pass through breast milk. Consult your doctor before taking it.
EVERGRAF 0.25MG TABLET should be taken with caution in patients with kidney problems. Consult your doctor before taking.
EVERGRAF 0.25MG TABLET should be taken with caution in patients with liver problems. Consult your doctor before taking.
Do not take EVERGRAF 0.25MG TABLET if you are allergic to Everolimus or any of the other ingredients of this medicine.
EVERGRAF 0.25MG TABLET should be taken with caution in patients with heart problems. Consult your doctor before taking [GBNKEYWROD].
There are no adequate data of the use of [GBNKEYWROD] in children and adolescents to support its use in patients in these age groups. Consult your doctor before taking [GBNKEYWROD].
EVERGRAF 0.25MG TABLET is generally not recommended for use in elderly patients (above 65 years of age). Consult your doctor before taking EVERGRAF 0.25MG TABLET.
Before taking EVERGRAF 0.25MG TABLET, inform your physician if you:
A. Drug-Drug interactions:
Before taking EVERGRAF 0.25MG TABLET, inform your doctor if you are taking any of the following medicine:
B. Drug-Food interactions:
Avoid having grapefruit or grapefruit juice while taking EVERGRAF 0.25MG TABLET as it may increase the risk of side effects.
Overdosage:
If you or anyone else accidentally takes too much of EVERGRAF 0.25MG TABLET, consult your doctor immediately or visit the nearby hospital.
| Drug | : | Everolimus |
| Pharmacological Category | : | Immunosuppressants |
| Therapeutic Indication | : | Prevention of organ rejection in transplant patients |
| Dosage Forms | : | Tablet |
Q: What for EVERGRAF 0.25MG TABLET used?
A: EVERGRAF 0.25MG TABLET is used for the prevention of organ rejection in transplant patients (organs like kidney, liver, or heart). It is used together with other medicines, such as ciclosporin for the transplantation of kidney and heart, tacrolimus for liver transplantation, and corticosteroids.
Q: How does EVERGRAF 0.25MG TABLET works?
A: EVERGRAF 0.25MG TABLET acts by suppressing the activity of the body's immune system and prevents the rejection of the transplanted organ.
Q: What are the common side effects of EVERGRAF 0.25MG TABLET?
A: The most common side effects of taking EVERGRAF 0.25MG TABLET are nausea, vomiting, diarrhea, stomach pain, infections, anemia, headache, anxiety. Contact your physician for advice if any of the symptoms worsen.
Q: Is it safe to use EVERGRAF 0.25MG TABLET in elderly patients?
A: EVERGRAF 0.25MG TABLET is generally not recommended for use in elderly patients (above 65 years of age). Consult your doctor before taking EVERGRAF 0.25MG TABLET.
Q: Is there any food to avoid while taking EVERGRAF 0.25MG TABLET?
A: Avoid having grapefruit or grapefruit juice while taking EVERGRAF 0.25MG TABLET as it may increase the risk of side effects. Consult your physician before taking EVERGRAF 0.25MG TABLET.
Q: Can I take EVERGRAF 0.25MG TABLET along with antiepileptics?
A: Antiepileptics like phenytoin, phenobarbital, or carbamazepine will affect the efficacy of EVERGRAF 0.25MG TABLET. Consult your doctor before taking EVERGRAF 0.25MG TABLET.
Q: Is it safe to use EVERGRAF 0.25MG TABLET in pregnant and breastfeeding?
A: EVERGRAF 0.25MG TABLET is generally not recommended for use in pregnant and breastfeeding women unless considered clearly necessary. Consult your doctor before taking EVERGRAF 0.25MG TABLET.
1. Alan M. Krensky, Jamil R. Azzi, and David A. Hafler. Immunosuppressants and Tolerogens. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 13th Edition. New York McGraw Hill Medical 2018. Page – 638-653.
2. Mei-Ling Yee and Hui-Hui Tan. Use of everolimus in liver transplantation. World Journal of Hepatology. August 2017. [Accessed on 11th June 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569278/
3. Tedesco H, Felipe C, de Sandes Freitas TV, Cristeli MP, Rodrigues C, Medina-Pestana JO. Impact of everolimus: update on immunosuppressive therapy strategies and patient outcomes after renal transplantation. Journals of Transplant Research and Risk Management. January 2011. [Accessed on 11th June 2022] https://www.dovepress.com/impact-of-everolimus-update-on-immunosuppressive-therapy-strategies-an-peer-reviewed-fulltext-article-TRRM
4. Jinyu Liu,Dong Liu,Juan Li,Lan Zhu,Chengliang Zhang,Kai Lei,Qiling Xu,Ruxu You. Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials. Journal of Plos One. January 2017. [Accessed on 11th June 2022] https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0170246
5. Damien Vitiello, Paul-Eduard Neagoe, Martin G Sirois & Michel White. Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation. Journal of Cellular & Molecular Immunology. June 2014. [Accessed on 11th June 2022] https://www.nature.com/articles/cmi201424
6. Novartis Pharmaceuticals UK Limited. Electronic Medicines Compendium (EMC). [Revised in May 2021] [Accessed 11th June 2021] https://www.medicines.org.uk/emc/files/pil.1920.pdf
7. Hikma Pharmaceuticals USA. dailymed.nlm.nih.gov. [Revised in May 2021] [Accessed on 11th June 2022] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf2dd54b-7a1d-4401-9a01-75e68235e433
8. Novartis Pharmaceuticals Corporation. US Food and Drug Administration. [Revised on January 2018] [Accessed on 11th June 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021560Orig1s022lbl.pdf#page=31
Written By Dr. Janet.C, Pharm.D
Last updated on 23 Mar 2023 | 03:21 PM(IST)